A randomized, open-label, controlled, multi-center Phase II study to evaluate the efficacy and safety of adecatumumab alone or sequentially to FOLFOX relative to FOLFOX after R0 resection of colorectal liver metastases

Primary objectives: To assess the effect of the monoclonal AB adecatumumab alone or sequentially to FOLFOX on 1 year disease-free survival (DFS) rates in colorectal cancer patients with complete (R0) resection of liver metastases
Primary endpoints: One year disease free survival (DFS) rate, defined by the ratio of disease-free patients one year after randomization to total patients per treatment arm